AD Pipeline Watch: Celldex Initiates Phase 2 Study of Barzolvolimab in AD
Celldex Therapeutics, Inc. has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD). Barzolvolimab is a humanized monoclonal antibody that specifically binds and blocks the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. “Two-thirds of patients treated […]